MONROVIA, Calif., April 26, 2017 /PRNewswire/ -- Xencor,
Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company
developing engineered monoclonal antibodies for the treatment of
autoimmune diseases, asthma and allergic diseases and cancer, today
announced that Bassil Dahiyat, Ph.D., president and chief
executive officer, will present at the 42nd Annual
Deutsche Bank Health Care Conference on Wednesday, May 3,
2017 at 12:50 p.m. ET in Boston, MA.
A live webcast of the presentation will be available on the
"Events & Presentations" section in the Investors section of
the Company's website located
at http://investors.xencor.com/events.cfm. A replay of the
presentation will be posted on the Xencor website
approximately one hour after the live event and will be available
for 30 days following the presentation.
About Xencor, Inc.
Xencor is a
clinical-stage biopharmaceutical company developing engineered
monoclonal antibodies for the treatment of autoimmune diseases,
asthma and allergic diseases and cancer. Currently, 11 candidates
engineered with Xencor's XmAb® technology are in clinical
development internally and with
partners. Xencor's internal programs include: XmAb®5871
in Phase 2 development for the treatment of IgG4-Related Disease,
and also for the treatment of Systemic Lupus Erythematosus;
XmAb®7195 in Phase 1 development for the treatment of asthma and
allergic diseases; XmAb®14045 in Phase 1 development for acute
myeloid leukemia; XmAb®13676 in Phase 1 development for B-cell
malignancies; and XmAb®18087 for the treatment of neuroendocrine
tumors, in pre-clinical development. Xencor's XmAb
antibody engineering technology enables small changes to the
structure of monoclonal antibodies resulting in new mechanisms of
therapeutic action. Xencor partners include
Novartis, Amgen, MorphoSys, Merck, CSL/Janssen, Alexion
and Boehringer Ingelheim. For more information, please
visit www.xencor.com.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/xencor-to-present-at-42nd-annual-deutsche-bank-health-care-conference-300445501.html
SOURCE Xencor, Inc.